Taysha advances TSHA-102 to pivotal trial with FDA BLA pathway; raises $215.6M

Filed May 6, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 15, 2025 · ~2 min read

Key Changes

• high

  FDA granted Breakthrough Therapy designation in September 2025; company finalized pivotal trial protocol with 6-month interim analysis potentially supporting BLA submission. Multiple patients dosed in Q4 2025, dosing completion expected Q2 2026.

  MD&A: Clinical Development verify on EDGAR →
• high

  Raised $215.6M in May 2025 equity offering and refinanced debt with $50M Trinity facility (down from 12.75% to 11.50% minimum rate), extending cash runway from Q4 2026 into 2028.

  MD&A: Financing Activities verify on EDGAR →
• high

  Special litigation committee moved to terminate derivative lawsuit related to August 2023 private placement; lead plaintiff does not oppose dismissal.

  Legal Proceedings verify on EDGAR →